Some interesting insights on off-label use - stroll to the bottom for a summary if you are interested but haven’t got time; otherwise, look for the framework that is useful for thinking about this from a physician’s point of view, which is how the regulator would like to “adopt” when thinking of the topic:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998554/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538391/
https://www.fda.gov/drugs/fdas-labeling-resources-human-prescription-drugs/prescribing-information-resources
(labeling resources page which includes a video to guide industry participants whose job it is to compile prescription information)
https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label
banter and General Discussion, page-9397
-
- There are more pages in this discussion • 447 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.040(3.76%) |
Mkt cap ! $1.170B | |||
| Open | High | Low | Value | Volume |
| $1.07 | $1.07 | $1.01 | $13.19M | 12.81M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 61090 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 239558 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |